Mesoblast Investors Shrug Off Positive Phase 2a Trial Data

April 1, 2016 11:22 AM | 1 min read | Make a Comment
Loading...
Loading...
Shares of
Mesoblast limited (ADR)MESO
were trading lower by more than 2 percent on Friday despite
announcing earlier in the day positive Phase 2a trial data. Mesoblast is engaged in the development of adult stem cell technology platforms. The company announced that results from a Phase 2a trial in patients with post-traumatic knee injury to their ACL showed that a single intra-articular injection of its mesenchymal precursor cell product candidate, known as MPC-75-IA, resulted in improvement in pain, function, cartilage thickness and joint structure among the 17 patients. The results of Mesoblast's study will be presented at the 2016 Osteoarthritis Research Society International (OARSI) World Congress in Amsterdam, The Netherlands. Professor Flavia Cicuttini, Head Musculoskeletal Unit, Department of Epidemiology and Preventive Medicine School of Public Health and Preventive Medicine at Monash University, Australia said: "These results are remarkable in that we were able to demonstrate significant improvements in patient symptoms and joint structure. We look forward to conducting a larger Phase 2/3 trial to confirm the observed significant long-term benefits in pain, function, and quality of life."
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: NewsACL InjuryMesoblastMPC-75-IAStem Cell
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!